文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

CagriSema作为基础胰岛素附加治疗2型糖尿病的3期研究

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
PubMed 文献 · Lancet · 2026-06-07

REIMAGINE 3是一项在6国46中心开展的双盲、随机、安慰剂对照3a期试验,纳入274例基础胰岛素治疗但血糖控制不佳的2型糖尿病患者。

要点

  • CagriSema每周一次皮下注射,在基础胰岛素基础上显著改善血糖控制。
  • 体重下降10-12%,安全性以轻中度胃肠道反应为主,无严重低血糖。

研究设计与样本

  • 双盲、平行组、随机、安慰剂对照3a期研究(REIMAGINE 3),在6国46中心开展。

主要发现

  • CagriSema带来10-12%的体重下降。

关键数值与推荐

  • 主要终点为所有随机分配参与者从基线至第40周HbA1c平均变化(百分点)。

临床怎么用

  • 对于基础胰岛素治疗血糖控制不佳的2型糖尿病患者,可考虑每周一次CagriSema作为附加治疗以显著改善血糖并减轻体重。
  • 治疗中需关注胃肠道不良反应,但无需担心额外低血糖风险。

局限性

  • 研究为40周短期随访,长期疗效和安全性需进一步观察。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia. We aimed to compare the efficacy and safety of a once per week combination of cagrilintide with semaglutide (CagriSema) versus placebo as an add-on to basal insulin in individuals with type 2 diabetes. METHODS: This double-blind, parallel-group, randomised, controlled, phase 3a study (REIMAGINE 3) was done at 46 centres (university hospitals, health-care centres, research centres, and other clinical trial sites) in six countries (the USA, China, Japan, Serbia, Slovakia, and South Africa). Adults with type 2 diabetes (glycated haemoglobin [HbA1c] 7·0-10·5%) receiving stable once per day basal insulin with or without metformin were randomly assigned (2:2:1:1) to once per week subcutaneous cagrilintide 2·4 mg plus semaglutide 2·4 mg (hereafter cagrilintide-semaglutide [2·4 mg each]) or cagrilintide 1·0 mg plus semaglutide 1·0 mg (hereafter cagrilintide-semaglutide [1·0 mg each]) or dose-matched placebo (2·4 mg plus 2·4 mg or 1·0 mg plus 1·0 mg) for 40 weeks. Randomisation was stratified by HbA1c of less than 8·5% at screening (yes or no) and country (Japan; yes or no). Participants, care providers, investigators, and outcome assessors were masked within each dose level to treatment allocation, with active treatments visually identical to placebo. The primary endpoint was mean HbA1c change (percentage points) from baseline to week 40 in all participants randomly assigned to treatment; secondary endpoints included change in bodyweight and safety, including hypoglycaemia. This trial was registered with ClinicalTrials.gov (NCT06323161) and is complete. FINDINGS: Between March 26 and Nov 29, 2024, we screened 340 individuals and 274 were included and randomly assigned to cagrilintide-semaglutide (2·4 mg each; n=90), cagrilintide-semaglutide (1·0 mg each; n=93), or placebo (pooled; n=91). Mean baseline HbA1c was 8·8% (SD 1·0), 159 (58%) participants were male, and 115 (42%) were female. Mean HbA1c reductions were significantly greater with cagrilintide-semaglutide (2·4 mg each -2·33% [SE 0·08] and 1·0 mg each -2·10% [0·08]) versus placebo (-0·66% [0·11]) at week 40, using the efficacy estimand (estimated treatment difference for cagrilintide-semaglutide [2·4 mg each] vs placebo -1·68 percentage points [95% CI -1·95 to -1·41], p<0·0001; for cagrilintide-semaglutide [1·0 mg each] vs placebo -1·44 percentage points [95% CI -1·71 to -1·17], p<0·0001). Cagrilintide-semaglutide provided bodyweight reductions of 10-12%. Adverse events were reported by 72 (80%) of 90 participants receiving cagrilintide-semaglutide (2·4 mg each), 66 (71%) of 93 receiving cagrilintide-semaglutide (1·0 mg each), and 65 (71%) of 91 receiving placebo, and were mostly mild or moderate gastrointestinal disorders. No severe hypoglycaemia was reported. There was one death in the cagrilintide-semaglutide (1·0 mg each) group not related to treatment (due to malignancy). INTERPRETATION: Cagrilintide-semaglutide at doses of 2·4 mg each and 1·0 mg each met the primary endpoint, with statistically significant and clinically relevant HbA1c reductions versus placebo when added to basal insulin-treated type 2 diabetes. These reductions were accompanied by robust bodyweight reduction and no additional risk of hypoglycaemia. The safety profile was consistent with that of the GLP-1 receptor agonist class and previous safety data for cagrilintide. Findings support the use of cagrilintide-semaglutide as an add-on to once per day basal insulin to significantly improve glycaemic control. FUNDING: Novo Nordisk.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Rosenstock J, Billings LK, Gajria R, et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet. 2026. PMID: 42251856. doi:10.1016/S0140-6736(26)01022-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。